These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38470375)

  • 1. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y
    Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
    Xin F; Yu YH; Shen XL; Zhang GX
    Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
    Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
    Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
    Shi H; Yang F; Cao M; Xu T; Zheng P; Guo Y; Su G; Feng S; Li R; Liu R; Liu H; Ma L; Ke X; Hu K
    Ann Hematol; 2024 Aug; 103(8):2993-3004. PubMed ID: 38662205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
    Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
    Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 9. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
    Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
    Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
    Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
    Shimony S; Garcia JS; Keating J; Chen EC; Luskin MR; Stahl M; Neuberg DS; DeAngelo DJ; Stone RM; Lindsley RC
    Leukemia; 2024 Jul; 38(7):1494-1500. PubMed ID: 38538860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
    Bewersdorf JP; Shimony S; Shallis RM; Liu Y; Berton G; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Bystrom RP; Lindsley RC; Chen EC; Ramos Perez J; Stein A; Pullarkat V; Aldoss I; DeAngelo DJ; Neuberg DS; Stone RM; Garciaz S; Ball B; Stahl M
    Blood Adv; 2024 Sep; 8(18):4845-4855. PubMed ID: 38941537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q; Liu L; Zhang Y; Li X; Wu D
    Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
    Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
    Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
    Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
    Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
    Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
    Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia.
    Wang YX; Wang A; Su YF; Wang J; Li YH; Li F; Jing Y; Xu L; Wang YZ; Zheng X; Gao CJ; Hu LD; Gao XN; Liu DH
    Front Immunol; 2024; 15():1409302. PubMed ID: 39221255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
    Lei M; Liu L; Wang Z; Wu D
    Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.
    Jin D; Chen H; He J; Li Y; Zheng G; Yang Y; Zhao Y; Le J; Shu W; He D; Cai Z
    Target Oncol; 2024 Mar; 19(2):237-249. PubMed ID: 38466536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Acker F; Chromik J; Tiedjen E; Wolf S; Vischedyk JB; Makowka P; Enßle JC; Kouidri K; Sebastian M; Steffen B; Oellerich T; Serve H; Neubauer A; Schäfer JA; Bittenbring JT
    Eur J Haematol; 2024 Nov; 113(5):623-630. PubMed ID: 39023132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.